Acceptance of cross-vaccination between journalists and non-journalists awaiting second dose of Sputnik V

Abstract

Introduction. In July 2021, approximately 40,000 Hondurans were awaiting their second dose of the Sputnik V COVID-19 vaccine, prompting the proposal to offer them cross-immunization. This group also included media personnel. This opinion poll assessed the acceptance and other perceptions regarding cross-immunization within this group. Methods. A rapid survey was conducted among media personnel and the general population, particularly older adults awaiting their second dose. Results. Responses were obtained from 146 individuals aged 21 to 95; 7 (4.8%) had already received their second dose, and 5 (3.4%) had previously received cross-immunization with another vaccine. Of the remaining 134 individuals, 35.8% (n=48) were media personnel, primarily reporters or presenters on radio and television. 67.9% of all participants expressed concern but preferred to wait for the arrival of the same vaccine brand. 29.8% believed that COVID-19 vaccines could be combined, but only 14.9% were willing to personally administer a cross-validation vaccine. 79.1% reported knowing little or nothing about the scientific basis for such vaccine cross-validation, with no difference between journalists and non-journalists. Half reported maintaining good biosafety standards, and the other half reported excellent standards. Conclusion: There was little acceptance of vaccine cross-validation, especially if it involved personal administration. A need for more scientific information on the subject was evident, particularly among media personnel.